RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+7.38%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.47B
AUM Growth
+$1.47B
(+2.7%)
Cap. Flow
-$26.1M
Cap. Flow
% of AUM
-1.77%
Top 10 Holdings %
Top 10 Hldgs %
26.19%
Holding
101
New
9
Increased
29
Reduced
33
Closed
7
Top Buys
| 1 |
Biogen
BIIB
|
$24.4M |
| 2 |
Veeva Systems
VEEV
|
$19.9M |
| 3 |
Pfizer
PFE
|
$19.6M |
| 4 |
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
|
$13.1M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$12.3M |
Top Sells
| 1 |
Johnson & Johnson
JNJ
|
$41.2M |
| 2 |
Bristol-Myers Squibb
BMY
|
$13.4M |
| 3 |
NovoCure
NVCR
|
$13.3M |
| 4 |
LivaNova
LIVN
|
$12.2M |
| 5 |
Eli Lilly
LLY
|
$11.8M |
Sector Composition
| 1 | Healthcare | 94.98% |
| 2 | Industrials | 1.94% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Guardant Health
GH
$8.11B
| $21.7M | 1.48% |
175,000
-50,000
| -22% | -$6.21M |
|
27
Intuitive Surgical
ISRG
$158B
| $20.7M | 1.4% |
67,500
-19,500
| -22% | -$5.98M |
|
28
Gilead Sciences
GILD
$140B
| $20.7M | 1.4% |
300,000
-50,000
| -14% | -$3.44M |
|
|
INOV
29
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $20.4M | 1.39% |
600,000
+385,000
| +179% | +$13.1M |
|
|
ABMD
30
DELISTED
Abiomed Inc
ABMD
| $20.3M | 1.38% |
65,000
-13,000
| -17% | -$4.06M |
|
31
Cencora
COR
$57.2B
| $19.8M | 1.34% |
173,000
+5,043
| +3% | +$577K |
|
|
32
Pfizer
PFE
$141B
| $19.6M | 1.33% |
+500,000
| New | +$19.6M |
|
|
BHVN
33
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $19.5M | 1.32% |
200,419
| – | – |
|
34
Apellis Pharmaceuticals
APLS
$3.51B
| $19.3M | 1.31% |
305,000
+35,000
| +13% | +$2.21M |
|
35
Exact Sciences
EXAS
$9.33B
| $19.3M | 1.31% |
155,000
-20,000
| -11% | -$2.49M |
|
36
Centene
CNC
$14.8B
| $19M | 1.29% |
260,000
-160,000
| -38% | -$11.7M |
|
37
Cooper Companies
COO
$13.3B
| $17.8M | 1.21% |
180,000
-20,000
| -10% | -$1.98M |
|
|
ITCI
38
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $17.5M | 1.19% |
429,728
-28,050
| -6% | -$1.14M |
|
39
Nektar Therapeutics
NKTR
$543M
| $16.3M | 1.11% |
63,333
-23,813
| -27% | -$6.13M |
|
|
ACCD
40
DELISTED
Accolade, Inc. Common Stock
ACCD
| $16.3M | 1.11% |
300,000
+100,000
| +50% | +$5.43M |
|
41
Phreesia
PHR
$1.81B
| $15.9M | 1.08% |
260,000
+200,000
| +333% | +$12.3M |
|
42
HCA Healthcare
HCA
$95.4B
| $15.5M | 1.05% |
75,000
| – | – |
|
43
McKesson
MCK
$85.9B
| $14.9M | 1.01% |
78,000
-10,000
| -11% | -$1.91M |
|
44
MacroGenics
MGNX
$121M
| $14.6M | 0.99% |
545,160
| – | – |
|
45
Regeneron Pharmaceuticals
REGN
$59.8B
| $14M | 0.95% |
25,000
+5,000
| +25% | +$2.79M |
|
46
BioMarin Pharmaceuticals
BMRN
$11.3B
| $13.4M | 0.91% |
160,000
-20,000
| -11% | -$1.67M |
|
47
Health Catalyst
HCAT
$228M
| $13.3M | 0.9% |
240,000
+125,000
| +109% | +$6.94M |
|
|
48
Johnson & Johnson
JNJ
$429B
| $12.4M | 0.84% |
75,000
-250,000
| -77% | -$41.2M |
|
|
RCM
49
DELISTED
R1 RCM Inc. Common Stock
RCM
| $12.2M | 0.83% |
550,000
+350,000
| +175% | +$7.78M |
|
50
Esperion Therapeutics
ESPR
$490M
| $12.1M | 0.82% |
572,267
-19,958
| -3% | -$422K |
|